ROSEMARIE SALERNI, M.D.; GERALD P. RODNAN, M.D., F.A.C.P.; DONALD F. LEON, M.D., F.A.C.P.; JAMES A. SHAVER, M.D., F.A.C.P.
SALERNI R, RODNAN GP, LEON DF, SHAVER JA. Pulmonary Hypertension in the CREST Syndrome Variant of Progressive Systemic Sclerosis (Scleroderma). Ann Intern Med. 1977;86:394-399. doi: 10.7326/0003-4819-86-4-394
Download citation file:
Published: Ann Intern Med. 1977;86(4):394-399.
Severe pulmonary hypertension without pulmonary fibrosis occurred in 10 patients with the CREST syndrome (calcinosis, Raynaud's phenomenon, esophageal dysfunction, sclerodactyly, telangiectasia), reputedly a benign variant of progressive systemic sclerosis. Time from the initial symptom, Raynaud's phenomenon, to the recognition of pulmonary hypertension was as long as 40 years. Pulmonary hypertension and increased pulmonary vascular resistance was shown in all patients. Autopsy examination in three of six deaths attributable to pulmonary hypertension showed intimal proliferation with myxomatous change in the small- and medium-sized pulmonary arteries similar to changes in the digital arteries of patients with scleroderma and Raynaud's phenomenon, and interlobular renal arteries of those with "scleroderma kidney." It is concluded that the CREST syndrome is not entirely benign but may be complicated, after a long clinical course, by progressive pulmonary vascular obliteration, pulmonary hypertension, and death in the absence of significant pulmonary fibrosis.
Learn more about subscription options.
Register Now for a free account.
Cardiology, Esophageal Disorders, Gastroenterology/Hepatology, Pulmonary Hypertension, Pulmonary/Critical Care.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only